#9: ILC2s and cancer

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/aa/40/7c/aa407ccb-022f-50b7-d8d2-d5f60ee3d038/mza_2161318956497004687.jpg/600x600bb.jpg

Inflammatory Content

Kellen Cavagnero, Ph.D.

27 episodes

5 days ago

Inflammatory Content is a podcast about immunology and biomedical sciences more broadly. UC San Diego immunologist Dr. Kellen Cavagnero PhD reviews the latest high-impact original articles and discusses all things science with leading researchers in the field. Inflammatory Content has been featured in Nature and received sponsorship from the NIH.

Science

RSS

All content for Inflammatory Content is the property of Kellen Cavagnero, Ph.D. and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Science

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/43221957/b129de24e713deee.jpg

#9: ILC2s and cancer

Inflammatory Content

13 minutes 16 seconds

5 years ago

#9: ILC2s and cancer

Cutting-edge approaches to combat tumor development involve transplantation of anti-tumor T cells and natural killer cells. Natural killer (NK) cells belong to a greater family of innate lymphoid cells which includes the more recently described group 1, 2, and 3 innate lymphoid cells (ILCs). Unlike NK and T cells, the role of non-NK ILCs in tumor immunity remains unclear. In this episode, Kellen highlights a 2020 report in Nature describing the role of ILC2s in pancreatic cancer. The article was written by John Alec Moral and colleagues and is titled “ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity”.

Paper: https://www.nature.com/articles/s41586-020-2015-4

Review: https://pubmed.ncbi.nlm.nih.gov/30209347/

To help us spread science, please consider writing a review, sharing this episode with your friends and colleagues, or donating to support our work (Venmo @Kellen-Cavagnero).

Please reach out to us via email (kcavagnero@gmail.com) or Twitter (@KellenCavagnero) with any questions, comments, topic suggestions, etc.